FDA grants priority review for Takeda and HUTCHMED’s fruquintinib NDA

26 May 2023
www.pharmaceutical-technology.com
NDAPriority ReviewPhase 3Clinical ResultDrug Approval
FDA grants priority review for Takeda and HUTCHMED’s fruquintinib NDA
Preview
Source: Pharmaceutical Technology
Fruquintinib has been developed for the treatment of adults with previously treated metastatic colorectal cancer. Credit: Kateryna Kon via Shutterstock.com.
The US Food and Drug Administration (FDA) has granted priority review for Takeda and HUTCHMED’s new drug application (NDA) for fruquintinib.
Fruquintinib is a selective and potent oral VEGFR -1, -2 and -3 receptors inhibitor and is used for the treatment of adults with previously treated metastatic colorectal cancer.
Recommended Reports
FDA grants priority review for Takeda and HUTCHMED’s fruquintinib NDA
Preview
Source: Pharmaceutical Technology
ReportsEnoyl [Acyl Carrier Protein] Reductase [NADH] FabI (NADH Dependent Enoyl ACP Reductase or Enoyl A... GlobalData
FDA grants priority review for Takeda and HUTCHMED’s fruquintinib NDA
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Tocilizumab Biosimilar in Cytokine Release Syndrome (Cytokine Storm) GlobalData
View all
Fruquintinib will be the first and only highly selective inhibitor of these receptors approved in the US for previously treated metastatic colorectal cancer.
It blocks tumour angiogenesis, improves kinase selectivity to minimise off-target toxicities and provides consistent target coverage.
The new drug application (NDA) included data from the Phase III FRESCO-2 and FRESCO trials.
The multi-regional clinical trial (MRCT) FRESCO-2 evaluated fruquintinib plus best supportive care (BSC) against placebo plus BSC.
This 691-patient study was conducted in Europe, the US, Japan and Australia. It met both the primary endpoint of overall survival and the key secondary endpoint of progression-free survival.
HUTCHMED research and development head and chief medical officer Dr Michael Shi stated: “The clinical benefit of fruquintinib has been confirmed in multiple ways, from global clinical studies to commercialisation in China.
“We are pleased to have Takeda as our partner furthering development and the commercialisation of fruquintinib outside of China.
“Today’s acceptance marks a significant advancement towards the goal of providing patients with previously treated metastatic colorectal cancer a much-needed therapeutic option, given the limited treatment options currently available to patients.”
The FDA has now assigned a prescription drug user fee act action date of 30 November 2023 for the NDA.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.